Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ADI-001 showed robust dose-dependent expansion and persistence in patients with relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma Strong exposure and persistence profile further...
Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Approximately 10.0% of the company’s stock are short sold. […]
Adicet Bio (NASDAQ:ACET – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends. Insider & Institutional Ownership 85.3% of Adicet […]
Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid's ...